title: [Cerebroprotective effect of 3-oxypyridine and succinic acid derivatives in acute phase of alloxan-induced diabetes mellitus in rats].
abstract: The effects of original domestic derivatives of 3-oxypyridine and succinic acid (emoxipine, reamberin, and mexidol) on cellular composition of cortical and diencephalic structures in rat brain were studied in parallel with monitoring of behavioral, conditional learning, and metabolic disorders in acute phase of alloxan-induced diabetes in rats. The efficiency of 3-oxypyridine derivatives was compared to the results of alpha-lipoic acid administration. Single administration of emoxipine, reamberin, and mexidol in optimal doses prevented lipofuscin deposition in CA1 field neurocytes in hippocampus and/or increased the amount of terminally differentiated cells ofneuroectodermal lineage (oligodendrocytes, pyramid and basket cells) in this zone ofpaleocortex. Concurrently conditional learning capacity in morbid animals was restored. The cerebroprotective and nootropic effects of emoxipine and reamberin were associated with increased exploration motivation in the open field and were independent of their effects on carbohydrate and lipid metabolism dysfunction. On the contrary, the neuroprotective and nootropic effects of mexidol were associated with additional inhibition of morbid rat activity in the open field and a decrease in the level of circulating products of lipid peroxidation. It is established that 3-oxypyridine and succinic acid derivatives significantly exceed alpha-lipoic acid in terms of neuroprotective effects but exhibit significantly lower hypolipdemic activity in acute phase of alloxan diabetes.
authors.forename: I A
authors.initials: IA
authors.lastname: Volchegorskiĭ
authors.forename: L M
authors.initials: LM
authors.lastname: Rassokhina
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Miroshnichenko
mesh_terms: D000496:Alloxan; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D005260:Female; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D007858:Learning / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology; D018697:Nootropic Agents / Q000494:pharmacology; D010847:Picolines / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D013386:Succinates / Q000494:pharmacology*; D019802:Succinic Acid / Q000737:chemistry / Q000494:pharmacology; D008063:Thioctic Acid / Q000494:pharmacology*
chemical_list: C457919:3-oxypyridine; D000975:Antioxidants; D001786:Blood Glucose; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D010847:Picolines; D011725:Pyridines; C549374:Reamberin; D013386:Succinates; C070020:emoxypine succinate; D008536:Meglumine; D000496:Alloxan; D008063:Thioctic Acid; D019802:Succinic Acid; C009820:6-methyl-2-ethyl-3-hydroxypyridine